Quick Answer
Ginkgo Bioworks Holdings, Inc. reported Cash and Equivalents of $167.20 million for fiscal year 2025.
Ginkgo Bioworks Holdings, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $167.20M | -70.2% |
| 2024 | $561.57M | -40.5% |
| 2023 | $944.07M | -28.3% |
| 2022 | $1.32B | -15.1% |
| 2021 | $1.55B | +307.0% |
| 2020 | $380.80M | -23.1% |
| 2019 | $495.29M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $111.06M | -82.0% | -45.4% |
| June 30, 2025 | $203.57M | -72.1% | -34.8% |
| March 31, 2025 | $312.42M | -62.8% | -44.4% |
| December 31, 2024 | $561.57M | -40.5% | -8.9% |
| September 30, 2024 | $616.21M | -41.3% | -15.6% |
| June 30, 2024 | $730.37M | -34.0% | -13.1% |
| March 31, 2024 | $840.44M | -30.3% | -11.0% |
| December 31, 2023 | $944.07M | -28.3% | -10.0% |
- Ginkgo Bioworks Holdings, Inc. showed a decrease of -70.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Ginkgo Bioworks Holdings, Inc.’s cash and equivalents has declined by 66.2% (from $495.29 million to $167.20 million).
- The most recent figure is from Ginkgo Bioworks Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: